RxDoctor Payments Data

Tara Paternoster

Physician Assistant · New Hyde Park, NYNPI 1720210792

Payments from drug & device makers

$1,327in general payments, 2019–2025

Across 48 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Progenics Pharmaceuticals, Inc.$247
  • Bayer$237
  • Verity Pharmaceuticals Inc.$104
  • Johnson & Johnson$102
  • Ferring Pharmaceuticals Inc.$87
  • Sumitomo Pharma America, Inc.$85
  • plus $465 from 12 others

What the payments were for

  • Food & beverage$1,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,327 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$17,730
Medicare patients
149
Services billed
1,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron60$58,951
MyrbetriqMirabegron55$48,326
XyostedTestosterone Enanthate39$24,824
Methenamine Hippurate193$14,961
Testosterone42$9,825
Estradiol72$5,608
Testosterone Cypionate75$3,880
Tamsulosin Hcl245$3,796
Potassium Citrate ErPotassium Citrate16$3,586
Solifenacin Succinate36$2,751
Tolterodine Tartrate ErTolterodine Tartrate29$2,339
Tadalafil13$1,820
Oxybutynin Chloride ErOxybutynin Chloride78$1,708
Finasteride102$1,575
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst70$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$85$58,95160 claims
Astellas Pharma US IncMyrbetriq$48$48,32655 claims
Antares Pharma, Inc.Xyosted$18$24,82439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →